Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.
about
A global approach to HIV-1 vaccine developmentMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeThe Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques.Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemicAssociation of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8(+) T-cell frequencies in a macaque AIDS modelQuantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.A neonatal oral Mycobacterium tuberculosis-SIV prime / intramuscular MVA-SIV boost combination vaccine induces both SIV and Mtb-specific immune responses in infant macaques.Virus-like particles produced in plants as potential vaccines.HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infectionA cure for AIDS: a matter of timing?Complex correlates of protection after vaccination.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Cell-mediated anti-Gag immunity in pharmacologically induced functional cure of simian AIDS: a 'bottleneck effect'?Meeting report VLPNPV: Session 5: Plant based technology.Virus-Like-Vaccines against HIV.
P2860
Q27024614-C1D200F3-9FE1-4807-A5E4-1318E9961F6AQ27318151-F8AA444A-46BD-4C35-9E26-AD5D6A02221DQ28608652-58624A7B-9BA7-4027-B45D-B2DF1B2C75DAQ30381239-A054A0C8-B41F-4BDC-89CC-99E1059F5BB4Q33597744-7985559B-95B1-408D-AABA-F1362B96B0BAQ33630150-11274FA2-BA15-4D6F-94CC-4901403C133DQ34261593-664528C0-8954-40B9-ACCB-1BFF273386F0Q35101608-01998648-9266-4812-9244-2C4303581BECQ35344875-8C1E2ADB-A0FB-4EC5-AFA3-2FAAC2B9301AQ35836048-C139C7CE-FEF1-47A2-AB09-DF9EB0D4122AQ35861190-A8AADD83-C267-44B2-A3E3-67150AFD1845Q36575637-C356B30B-B0C1-4789-B5CF-EAF52E8E53D3Q37121711-4A9328C5-F110-4512-B7FB-43F3B13DDF36Q37123237-D3452FA7-FD25-4767-AB47-0DDAD0EC2D59Q37355237-B14EF853-D886-4A05-A258-45A2095BC5D6Q37490057-52D5A881-A716-4D96-AD51-EC3CAC4B6CA0Q38081975-AC06DCF6-6D36-4C39-8367-502A9A8F90E1Q38105946-8A9FC905-7383-450D-AA38-AF522CF6CE17Q38165451-7EB05D49-30CA-465B-83DF-1D410FDF7B7FQ38456515-05E29355-ADB6-423A-8CC3-D61F1CC5D3ACQ40220988-4E8B615C-B0C7-474C-8DE1-AB02B1FEFCFFQ40853026-AFA7E642-05F2-4713-A428-1C423BDE67B0Q42346870-DE9DC924-2950-4F81-A5E3-52FED8AF02ACQ50034030-532DE7AF-D390-49C7-B191-AC0D61BDDFE3
P2860
Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@ast
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@en
type
label
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@ast
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@en
prefLabel
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@ast
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@en
P2093
P2860
P356
P1433
P1476
Gag-specific cellular immunity ...... of vaccinated rhesus monkeys.
@en
P2093
Bruce D Walker
Kathryn E Stephenson
P2860
P304
P356
10.1128/JVI.00996-12
P407
P577
2012-07-03T00:00:00Z